In this issue:
A care coordinator model for cardiovascular risk interventions
Tyrosine kinase 2 inhibition with zasocitinib in psoriasis
16- vs 8-week guselkumab in super responders
Insulin resistance impairs biologic agent response
IL-23 vs IL-12/23 inhibition for preventing incidental PsA
ERAP1 and ERAP2 gene variants as biomarkers of anti-IL-17A response
Tapinarof cream for the treatment of plaque psoriasis
Predictors of initiating biologics in the treatment of psoriasis
Adherence to IL-17A inhibitors and resolution of GPP
Diabetes/obesity and improvement in cardiometabolic parameters with apremilast
Please login below to download this issue (PDF)